AAV-GAD
MeiraGTx’s Gene Therapy Shows Significant Improvements in Motor Function and Quality of Life in Parkinson’s Disease Trial
MeiraGTx, Gene Therapy, Parkinson’s Disease, AAV-GAD, Motor Function, Quality of Life, Clinical Trial, Phase 2 Trial, Neurodegenerative Disease, Dopamine Replacement, GABA Production
MeiraGTx Announces Positive Phase 2 Data for AAV-GAD Gene Therapy in Parkinson’s Disease, Paving Way for Phase 3 Trial
MeiraGTx, AAV-GAD, Gene Therapy, Parkinson’s Disease, Phase 2 Trial, Phase 3 Trial, Neurodegenerative Disorders, Genetic Medicine